Sydnexis
Del Mar
About Sydnexis
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $50.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2021)
- Website: sydnexis.com
- Phone: (619) 507-9827
Industries & Categories
Manufacturing, Pharmaceutical
Canonical: https://fsome.com/organization/sydnexis-127646 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.